Back to dashboard
MedicaidPrior AuthLow impact

Empliciti (elotuzumab) (New)

Humana·IN · Oncology, Hematology·Medicaid
Effective date
Oct 1, 2025
We identified it
Jun 24, 2026
Days to comply

Summary

Humana Medicaid (Indiana) has implemented a new prior authorization policy for Empliciti (elotuzumab), an IV cancer medication used to treat multiple myeloma. Prior authorization is required with specific criteria including diagnosis confirmation and specific combination therapy requirements.

Action Required

Action needed
By October 1, 2025: Billing team must obtain prior authorization for all Empliciti (elotuzumab) prescriptions for Indiana Medicaid patients with multiple myeloma. Ensure documentation includes diagnosis confirmation, prior therapy history, and planned combination therapy regimen. Update prior authorization workflows to include 6-month approval durations.